Asset profile
Daraxonrasib · Rasonque
Small molecule
Evidence outlook
Approved: Pancreatic Ductal Adenocarcinoma (label: metastatic disease after at least one prior systemic therapy, or not a candidate for multiagent...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Non-Small Cell Lung Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 62 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Daraxonrasib (Rasonque): this drug | Approved | Small molecule | pan-RAS, RAS (pan-RAS, RAS-mutant tumors) | ||
| JYP0015 | Phase 2 | Small molecule | pan-RAS | ||
| BPI-572270 | Phase 1/2 | Small molecule | RAS (pan-RAS, RAS-mutant tumors) | ||
| GFH276 | Phase 1/2 | Small molecule | pan-RAS | ||
| ERAS-0015 | Phase 1 | Small molecule | pan-RAS | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(15 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
October 2026 (1)
What to watch
December 2026 (1)
What to watch
2027 (4)
May 2027 (1)
What to watch
June 2027 (2)
December 2027 (1)
What to watch
2028 (5)
April 2028 (1)
What to watch
June 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (3)
May 2029 (2)
June 2029 (1)
What to watch
2030 (1)
November 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.